GSK5182 is primarily used in scientific research as a selective inverse agonist of the estrogen-related receptor gamma (ERRγ). It is employed to study metabolic pathways, particularly those involved in energy homeostasis, mitochondrial function, and glucose metabolism. Researchers use GSK5182 to investigate the role of ERRγ in conditions such as diabetes, obesity, and cancer, where altered energy metabolism plays a key role. By modulating ERRγ activity, GSK5182 helps in understanding the receptor’s impact on gene expression related to oxidative phosphorylation and metabolic regulation. Its application remains confined to preclinical studies and is not used in clinical or therapeutic settings.